Drugs News and Research

RSS

Research provides hope and encouragement to people living with lupus

Research presented during the 9th International Lupus Congress held in Vancouver, Canada from June 24-27, 2010 should give hope and encouragement for the future of the treatment and management of lupus to the 1.5 million Americans and 5 million people worldwide living with lupus. In recent years, there have been significant advances made in many areas of lupus research including the development of new treatments, adult stem cell transplantation, genetics, lupus-related cardiovascular disease, and quality of life issues for people with lupus.

25 Jun 2010

New method to synthesize drug candidates for testing

Some drugs may be more effective the longer they last inside the body. To prevent such drugs from being broken down too rapidly, pharmaceutical manufacturers often attach a fluorine-containing structure called a trifluoromethyl group. However, the processes now used require harsh reaction conditions or only work in a small number of cases, limiting their usefulness for synthesizing new drug candidates for testing.

25 Jun 2010

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

There's been little change over the last three years in how patients rate the care they receive in Saskatchewan hospitals, according to a report released today by the province's Health Quality Council. The report, entitled Quality Insight 2010, presents an overview of aspects of quality of care delivered in hospitals, in the community for people living with certain chronic diseases, and for seniors taking prescription drugs.

25 Jun 2010

PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration: Researchers

The way prostate cancer develops in men who have an altered 'breast cancer gene' is the same route by which breast cancer develops in women with the same mutation, reveals a study published in PLoS Genetics today (Thursday).

25 Jun 2010

U.N. Secretary-General to ask G20 for additional $60B over 5 years for maternal, child health

U.N. Secretary-General Ban Ki-moon said he plans to ask the G20 to follow through on aid promises and to commit an additional $60 billion over five years for lowering maternal and child mortality rates worldwide, Bloomberg Businessweek reports.

25 Jun 2010

Minnesota AIDS Project awarded federal grant to support HIV prevention services for young gay, bisexual men

The Minnesota AIDS Project is pleased to announce that it has been notified that it will be awarded a federal grant for five years totaling over $1.5 million from the Centers for Disease Control targeting HIV prevention services for young gay and bisexual men in Minnesota. This segment of the community represents the fastest growing population of HIV infections in Minnesota with the total number of new cases in 2009 at the highest level since 1994. The Minnesota AIDS Project Board of Directors is focusing its efforts to reduce these numbers and is committed to using the funds to target these prevention services.

25 Jun 2010

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

We've all experienced the strong heartbeat that accompanies emotions such as fear and rage. But can the body's natural response to these emotions be used to combat heart failure? Results of a study published online today in the journal Circulation Research present a strong case.

25 Jun 2010

Opinions: Harper and global health; Health workers in developing countries; Funding commitments; DDT, GMO use

Canadian Prime Minister Stephen Harper "can use the relatively intimate setting of the G8's Muskoka meeting to press for a renewal of the G8's commitment to better health for Africans, and help the developed world be truly accountable for its promises," the Globe and Mail writes in an editorial. "The G8's failure to fully fund the historic aid commitments to Africa it made at the 2005 Gleneagles summit" puts the future success of the developing world at risk, the editorial states.

25 Jun 2010

Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease initiated

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.

25 Jun 2010

Recovering addicts who avoid coping with stress more likely to relapse during recovery

Recovering addicts who avoid coping with stress succumb easily to substance use cravings, making them more likely to relapse during recovery, according to behavioral researchers.

25 Jun 2010

Conn. AG launches probe of CVS prescription plan termination threat

Richard Blumenthal, the Connecticut attorney general and a candidate for the U.S. Senate, announced an investigation of CVS Caremark after the corporation threatened to terminate a discount prescription drug program, Dow Jones Newswires/The Wall Street Journal reports.

25 Jun 2010

Correlation exists between synaptic plasticity and drug addiction

Why is it that only some drug users become addicts? This is the question that has been addressed by the teams of Pier Vincenzo Piazza and Olivier Manzoni, at the Neurocentre Magendie in Bordeaux (Inserm unit 862). These researchers have just discovered that the transition to addiction could result from a persistent impairment of synaptic plasticity in a key structure of the brain.

25 Jun 2010

Devastating 21% SGR cuts to Medicare disproportionately impact cancer care

Today a group of cancer patients, oncologists, oncology nurses and practice administrators will meet with Members of Congress to speak out about the enormous burden placed by the massive Medicare cuts to U.S. cancer care, and to offer solutions.

24 Jun 2010

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

24 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that patients are being enrolled in a Phase 1 clinical trial evaluating IPI-493 in patients with advanced hematologic malignancies. This multi-center study is the second clinical trial of IPI-493, Infinity's oral heat shock protein 90 (Hsp90) chaperone inhibitor.

24 Jun 2010

Individuals get involved in alcohol or drug related accidents during summer holidays

As the days grow longer and hotter, some chemical dependency professionals have their own name for summer: substance abuse season, because that's when individuals who abuse or are addicted to alcohol, prescription medications and drugs get involved in alcohol or drug related accidents during the summer holidays.

24 Jun 2010

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Palatin Technologies, Inc. today announced the completion of patient dosing and database lock in a double-blind, placebo-controlled, multiple dose, crossover study of bremelanotide, its subcutaneously administered melanocortin agonist for treatment of erectile dysfunction (ED). Palatin expects to report top-line data in the next calendar quarter.

24 Jun 2010

Blood flow disturbances in artery determine appearance of atherosclerosis: Study

A new animal model of atherosclerosis has allowed researchers to identify a host of genes turned on or off during the initial stages of the process, before a plaque appears in the affected blood vessel.

24 Jun 2010

UNC team provides first example of successful radiomitigation in mammals

While radiation has therapeutic uses, too much radiation is damaging to cells. The most important acute side effect of radiation poisoning is damage to the bone marrow. The bone marrow produces all the normal blood cells, and therefore a high dose of radiation can lead to low blood counts of red cells, platelets and white blood cells.

24 Jun 2010

Drugs News and Research

Research provides hope and encouragement to people living with lupus

New method to synthesize drug candidates for testing

HQC report presents different aspects of health care delivered in Saskatchewan hospitals

PARP inhibitors may be effective in men with prostate cancer due to BRCA2 alteration: Researchers

U.N. Secretary-General to ask G20 for additional $60B over 5 years for maternal, child health

Minnesota AIDS Project awarded federal grant to support HIV prevention services for young gay, bisexual men

Two experimental drugs have potential to restore pumping strength to failing hearts, study finds

Opinions: Harper and global health; Health workers in developing countries; Funding commitments; DDT, GMO use

Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease initiated

Recovering addicts who avoid coping with stress more likely to relapse during recovery

Conn. AG launches probe of CVS prescription plan termination threat

Correlation exists between synaptic plasticity and drug addiction

Devastating 21% SGR cuts to Medicare disproportionately impact cancer care

Cellonis' stem cells diabetes treatment helps reconstruct natural insulin production

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Infinity commences enrollment in IPI-493 Phase 1 clinical trial for advanced hematologic malignancies

Individuals get involved in alcohol or drug related accidents during summer holidays

Palatin announces completion of patient dosing, database lock in bremelanotide study for ED

Blood flow disturbances in artery determine appearance of atherosclerosis: Study

UNC team provides first example of successful radiomitigation in mammals

Drug Discovery - Second Edition eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News